Opus Genetics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Opus Genetics, Inc. (IRD) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$15.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Opus Genetics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$15.48M.
- Opus Genetics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$7.42M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$15.48M 10-Q · filed 2026-08-06 | -$73.63M 10-Q · filed 2026-08-06 |
| 2025-06-30 | -$7.42M 10-Q · filed 2026-08-06 | -$15.61M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |